Loading
Life sciences · Journal article
Synthetic and Systems Biotechnology · September 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Effective biomarker detection is critical for timely and accurate clinical disease diagnosis. However, conventional analytical methodologies are often constrained by laborious procedures, reliance on specialized equipment, and an inherent inability to perform continuous in situ monitoring. To circumvent these limitations, synthetic biology has pioneered the development of genetically encoded biosensors as a rapid, highly sensitive, and cost-effective alternative. This review specifically focuses on transcriptional regulation-based biosensors, primarily those utilizing allosteric transcription factors (aTFs) and two-component systems (TCSs). By integrating these regulatory sensing modules into engineered microbial chassis, researchers can achieve continuous, real-time biomarker monitoring even within complex and otherwise inaccessible physiological environments. This review particularly focuses on microbial chassis rather than mammalian systems due to their highly tractable genetics, rapid response kinetics, and their unique potential to be deployed as autonomous living probiotics for in situ theranostics. Furthermore, coupling these sensors with engineered actuator genes enables the construction of intelligent therapeutic genetic circuits. This closed-loop theranostic paradigm facilitates simultaneous, real-time diagnosis and autonomous, localized therapeutic interventions, paving the way for personalized and dose-adaptive precision medicine. Finally, we summarize recent advancements in these biosensor platforms, explore their applications in targeted disease interventions, and discuss the contemporary challenges alongside future perspectives for their clinical translation.